Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention
Matthew D. Vesely, Sean R. Christensen
Matthew D. Vesely, Sean R. Christensen
Published January 2, 2025
Citation Information: J Clin Invest. 2025;135(1):e188018. https://doi.org/10.1172/JCI188018.
View: Text | PDF
Commentary

Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention

  • Text
  • PDF
Abstract

Cutaneous squamous cell carcinoma (cSCC) incidence and deaths continue to rise, underscoring the need for improved cSCC prevention. Elimination of actinic keratosis (AK) precursor lesions is a major strategy to prevent cSCC. Topical calcipotriol and 5-fluorouracil (5-FU) have been shown to eliminate AKs and reduce the risk of cSCC development, but the mechanism was undefined. In this issue of the JCI, Oka et al. demonstrate that type 2 immunity is necessary and sufficient for the elimination of premalignant keratinocytes and cSCC prevention. Paired biopsies from AK lesions and unaffected skin revealed that only keratinocytes from AKs produced thymic stromal lymphopoietin (TSLP) and damage-associated molecular patterns, resulting in selective recruitment of Th2 cells to the AK lesion. In mouse models of skin carcinogenesis, TSLP was necessary to recruit Th2 cells and trigger IL-24–mediated keratinocyte cell death. These findings suggest that the TSLP/Th2/IL-24 axis is a potential therapeutic target for SCC prevention.

Authors

Matthew D. Vesely, Sean R. Christensen

×

Figure 1

Topical calcipotriol plus 5-FU stimulates immune surveillance in actinic keratosis and squamous cell carcinoma.

Options: View larger image (or click on image) Download as PowerPoint
Topical calcipotriol plus 5-FU stimulates immune surveillance in actinic...
Sun-damaged skin harbors areas of normal epidermis mixed with areas of actinic keratosis, composed of transformed keratinocytes with dysregulated proliferation and differentiation, due to UV-induced somatic mutations. Topical calcipotriol induces TSLP production by transformed keratinocytes in actinic keratosis but not in unaffected keratinocytes. TSLP is recognized by T cells in the dermis and stimulates Th2 differentiation. Keratinocyte injury, mediated by the chemotherapeutic agent 5-FU, leads to expression of damage-associated molecular patterns including Annexin A1, Calreticulin, and MHC class II, which further promote T cell activation and proliferation. Activated Th2 cells secrete IL-4 and IL-13, which specifically stimulate transformed keratinocytes to express IL-24. IL-24 acts in an autocrine and paracrine fashion on transformed keratinocytes to enhance apoptosis, autophagy, and general cell death. In addition, ongoing stimulation of dermal T cells facilitates development of resident memory T cells (TRM) in the skin, allowing for long-term immunosurveillance and elimination of squamous cell carcinoma and its precursors.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts